J.Jpn. Surg. Soc.. 80(12): 1424-1426, 1979

---

Report on the annual meeting

BCG THERAPY AS AN ADJUVANT TO SURGERY FOR LUNG CANCER
―A RANDOMIZED CONTROLLED STUDY―

Intradermal BCG was given to the resectable lung cancer cases. Protocol was consisted with 5 times of BCG, once 2 weeks before surgery and 4 times consecutively after surgery with one month interval. One of the intentions of this protocol is to prevent the decrease in immune status resulted from surgery and general anesthesia by a preoperative use of BCG.
There were 57 BCG Cases and 71 control cases. At risk at 30 month after surgery, BCG group revealed survival rate of 65.3% and in control group it was 45.3% according to the life table method. The difference between the two was statistically significant.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.